Section Arrow
CRDL.NASDAQ
- Cardiol Therapeutics
Quotes are at least 15-min delayed:2026/05/13 07:58 EDT
Pre Market
Last
 1.332
-0.018 (-1.33%)
Bid
1.33
Ask
1.37
High 1.3705 
Low 1.3307 
Volume 2.05K 
Regular Hours (Closed)
Last
 1.35
+0.015 (+1.12%)
Day High 
1.35 
Prev. Close
1.335 
1-M High
1.71 
Volume 
358.90K 
Bid
1.33
Ask
1.37
Day Low
1.3 
Open
1.33 
1-M Low
1.27 
Market Cap 
149.09M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.33 
20-SMA 1.4 
50-SMA 1.24 
52-W High 1.71 
52-W Low 0.88 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.39/-0.23
Enterprise Value
149.18M
Balance Sheet
Book Value Per Share
0.12
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
HIMSHims & Hers Health25.03-4.11-14.10%57.14PE
Pre Market 24.85 -0.18 -0.72%
ZTSZOETIS76.94+0.27+0.35%12.61PE
Pre Market 77.45 +0.51 +0.66%
CPHIChina Pharma Holdings Inc0.8927+0.35855+67.13%-- 
Pre Market 0.859 -0.0337 -3.78%
VTRSViatris17.17+0.25+1.48%-- 
Pre Market 17.17 0 0.00%
ELANElanco Animal Health21.43-0.29-1.34%-- 
Pre Market 21.54 +0.11 +0.51%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.